ANNLIA PAGANINI-HILL, Ph. D.; RONALD K. ROSS, M.D., M.S.; VIBEKE R. GERKINS, R.N., M.P.H.; BRIAN E. HENDERSON, M.D.; MARY ARTHUR, B.S.; THOMAS M. MACK, M.D., M.P.H.
PAGANINI-HILL A, ROSS RK, GERKINS VR, HENDERSON BE, ARTHUR M, MACK TM. Menopausal Estrogen Therapy and Hip Fractures. Ann Intern Med. 1981;95:28-31. doi: 10.7326/0003-4819-95-1-28
Download citation file:
Published: Ann Intern Med. 1981;95(1):28-31.
The association between menopausal estrogen therapy and hip fracture was studied in a retirement community. Ninety-one hip fracture cases during a 5-year period in female residents under age 80 were compared to age-and race-matched community controls. Estrogen use was recorded from the medical records of the outpatient care facility and personal interviews. The estimated risk ratio for use of oral estrogens in excess of 60 months was 0.42. This protective effect was largely limited to oophorectomized women for whom the risk ratio for a comparable duration of use was 0.14; the risk significantly decreased with increased duration, but no such trend existed with increased dosage. Diabetes mellitus, low Quetelet's index, tallness, prolonged immobilization or physical inactivity, use of corticosteroids, early age at menopause, low levels of sunlight exposure, and heavy cigarette smoking were each independent risk factors for hip fracture but none confounded the observed association with estrogen use.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Coronary Risk Factors, Diabetes, Education and Training, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only